| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 9,735 | 9,883 |
| Effects of exchange rate changes on cash and cash equivalents | -44 | 62 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -4,131 | 461 |
| Cash and cash equivalents at beginning of period | 11,705 | - |
| Cash and cash equivalents at end of period | 7,574 | - |
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)